Clearside BioMedical, Inc Stock News

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0.00% and -75.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the sto

\- IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) - \- Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs - \- Engaged New Contract Manufactu

\- Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020 - ALPHARETTA, Ga., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceuti

Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...

ALPHARETTA, Ga., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALPHARETTA, Ga., July 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi

ALPHARETTA, Ga., July 27, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi

Zacks Investment Research upgraded shares of Clearside Biomedical (NASDAQ:CLSD) from a hold rating to a buy rating in a report published on Monday morning, Zacks.com reports. They currently have $2.25

Clearside Biomedical, Inc. (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

Wedbush analyst Liana Moussatos reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report) today and set a price

The Nasdaq is within reach of all-time highs made last week. With the amount of fiscal and monetary stimulus on the table, and the economy seemingly rebounding from the lows, will it be enough to keep

– Preclinical CLS-AX data demonstrates a potentially long-acting therapy for neovascular age-related macular degeneration – – Evidence supports the reliability, repeatability,.

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes

Which stocks tend to polarize market watchers? Penny stocks. Out on Wall Street, investors have strong opinions when it comes to these divisive tickers, which trade for less than $5 per share.The penn